Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at [email protected].
Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs
August 18th 2025This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.
Goodpath Partners With GiftHealth to Expand Access to GLP-1 Therapies Through LillyDirect
August 15th 2025The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to support safe use, adherence, and management of related chronic health needs.
Gross-to-Net Bubble Reshapes Drug Pricing Strategy
August 15th 2025As over half of Americans now receive prescriptions through Medicare or Medicaid, pharma companies must shift from a commercial-first approach to a statutory-first model, making GTN governance a C-suite priority for long-term brand survival.
Pharma Pulse: US API Stockpile Plan, Mounjaro Price Hike in UK, and New Data on Vaccine Safety
August 15th 2025This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price increase for Mounjaro in the UK, and long-term research confirming the safety of aluminum in childhood vaccines.
How a 250% Tariff Might Ripple Through Pharma Supply Chains and Spur Domestic Production
August 14th 2025In the second part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, outlines how the impact of a steep pharmaceutical import tariff varies across raw materials, components, and finished products, along with why such a policy could incentivize companies to shift production to the US.
AI-Powered Counterfeit Drug Schemes Pose Growing Threat to Patient Safety
August 13th 2025In the first part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, warns that counterfeiters are using generative AI to clone pharmaceutical packaging, build convincing fake websites, and manipulate search results. rapidly outpacing enforcement efforts and putting patients at serious risk.
AbbVie Invests $195 Million to Expand Stateside API Manufacturing
August 13th 2025The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology, neuroscience, and oncology therapies, reinforcing US pharmaceutical capacity amid industry reshoring and tariff concerns.
Potential 250% Pharma Tariffs Could Pressure Margins Without Directly Raising Patient Costs
August 12th 2025In the first part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, explains how steep pharmaceutical import tariffs might affect costs at different points in the supply chain, why component pricing poses a bigger risk than active ingredients, and how insurers, distributors, and manufacturers may negotiate to shield patients from price increases.
Hospital Networks Invest in Centralized Pharmacy Hubs to Cut Costs and Strengthen Supply Chains
August 12th 2025Health systems across the United States are opening large-scale pharmacy service centers to streamline operations, improve inventory control, and ensure timely medication delivery amid drug shortages and rising costs.
How Pharma Can Remain Competitive Amid Rising Healthcare Costs
August 11th 2025In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses operational and pricing strategies pharma executives can adopt to navigate sustained cost inflation, including supply chain optimization, payer collaboration, and value-based approaches to ensure patient access and affordability.
Peer Exchange: Maximizing Supply Chain Efficiency Without Overreacting to Tariffs (Episode 7)
August 8th 2025In the seventh part of this roundtable discussion, key opinion leaders uncover how pharma companies can mitigate tariff impact through duty drawback programs and smart technology investments, without overreacting or overhauling manufacturing footprints unnecessarily.
Balancing AI Ambition With Cost Pressures in Pharma
August 7th 2025In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, explains how pharma companies can strategically evaluate AI investments across functions like R&D, pharmacovigilance, and supply chain, ensuring early automation gains and long-term value without intensifying short-term financial strain.
Ways Pharma Supply Chains Can Cut Scope 3 Emissions Now
August 6th 2025In the final part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, outlines practical, cost-conscious strategies for reducing Scope 3 emissions in pharma supply chains, from smarter warehouse lighting and returnable cold chain packaging, to order consolidation and AI-enabled delivery optimization.
Novo Nordisk Ramps Up Legal Fight Against Compounded Semaglutide Knockoffs
August 6th 2025With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect patients from unapproved compounded semaglutide products by targeting pharmacies, telehealth providers, and deceptive marketing practices that compromise safety, mislead consumers, and violate FDA regulations.
How Pharma Can Navigate Innovation and Cost Pressures in the GLP-1 Era
August 6th 2025In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses how the pharmaceutical industry is balancing high-cost innovation, especially in obesity and metabolic disease, with payer demands for cost containment, highlighting the growing role of biosimilars and future generics in offsetting spend.
Lessons From Shortages and Global Disruptions
August 5th 2025In the fifth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.